VivoSeq
Oncology

Carcinoma of Unknown Primary

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Carcinoma of Unknown Primary is an early-stage landscape with 0 programs across 1 company. The most active players are Suzhou Suncadia Biopharmaceuticals Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

11

clinical trials

Completed6 · 55%
Unknown status2 · 18%
Terminated2 · 18%
Not yet recruiting1 · 9%

Clinical Trials

Trial Activity

11 trials

Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary
Not yet recruiting·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT07434180·20 enrolled
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
Completed·SSCRI Development Innovations, LLC·Phase 3·NCT00193596·198 enrolled
Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site
Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00360360·60 enrolled
Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193609·48 enrolled
Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193622·50 enrolled
Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00737243·289 enrolled
A Multi-Centre, Single Arm, Phase 2 Trial of Pembrolizumab in Treatment Naïve Patients With Poor-Prognosis Carcinoma of Unknown Primary Site
Completed·AAHS Cancer Control Alberta·Phase 2·NCT03391973·33 enrolled
Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site
Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00148135
Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary
Terminated·HHoosier Cancer Research Network·Phase 2·NCT03396471·14 enrolled
Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary
Unknown status·SSamsung Medical Center·Phase 2·NCT02590055·29 enrolled
Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary
Unknown status·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT00126269·192 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)